Table 4 The main pharmacokinetic parameters of tepotinib in different treatment groups of rats. Group A: the control group (0.5% CMC-Na); Group B: 50 mg/kg naringenin. (n = 5, mean ± SD)
From: Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
Parameters | Group A | Group B |
|---|---|---|
AUC0→t (ng/mL•h) | 4596.47 ± 458.17 | 5802.37 ± 895.75* |
AUC0→∞ (ng/mL•h) | 4630.42 ± 453.80 | 5995.51 ± 937.05* |
MRT0→t (h) | 18.93 ± 1.21 | 18.56 ± 3.16 |
MRT0→∞ (h) | 19.43 ± 1.36 | 18.96 ± 3.45 |
t1/2 (h) | 9.40 ± 2.35 | 12.49 ± 4.52 |
Tmax (h) | 8.80 ± 3.03 | 10.40 ± 2.19 |
CLz/F (L/h) | 10.88 ± 1.04 | 8.52 ± 1.46* |
Cmax (ng/mL) | 180.28 ± 38.25 | 267.69 ± 95.87 |